[Form 4] ATAI Life Sciences N.V. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: ATAI Life Sciences N.V. reported that director Laurent Fischer was granted a new option award on 26 June 2025.

Key details:

• Derivative security: Stock option on ATAI common shares
• Quantity granted: 103,000 options
• Exercise price: $2.25 per share
• Expiration: 26 June 2035
• Vesting: Options vest on the earlier of (i) the day before the company’s next annual meeting or (ii) 26 June 2026.
• Ownership status: Following this transaction, the reporting person beneficially owns 103,000 derivative securities, held directly.

The filing represents a routine equity compensation grant to a non-executive director and does not disclose any purchase or sale of ATAI common shares. No cash consideration was exchanged at grant (price of derivative security recorded as $0), indicating a standard incentive award. The disclosure offers no new information on company operations, earnings, or strategic developments.

Insights

Financial Analyst

TL;DR: Routine director option grant, immaterial to ATAI valuation or near-term share supply.

The issuance of 103,000 options at a $2.25 strike aligns director incentives but is small relative to ATAI’s outstanding share count. No common shares changed hands, and dilution will occur only if the options are exercised at or above the strike before 2035. As such, the filing is largely administrative with negligible impact on cash flow, leverage, or earnings projections. Investors may view insider equity awards as modestly positive for alignment, yet the quantitative effect is immaterial.

Corporate Governance Expert

TL;DR: Standard non-executive compensation; governance practices appear consistent with peer norms.

Granting long-dated, time-based options to a director supports shareholder alignment without immediate cost to the company. Vesting tied to the next AGM or one-year horizon is typical, ensuring directors maintain engagement over the coming governance cycle. No accelerated vesting or unusual terms were disclosed. Overall, the filing signals adherence to standard Section 16 reporting and poses no governance red flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischer Laurent

(Last) (First) (Middle)

C/O ATAI LIFE SCIENCES N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183 AT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.25	06/26/2025		A		103,000		(1)	06/26/2035	Common Shares	103,000	$0	103,000	D

Explanation of Responses:

1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

	/s/ Ryan Barrett, Attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ATAI (ATAI) disclose in the latest Form 4?

The company reported a grant of 103,000 stock options to director Laurent Fischer on 26 June 2025 at a $2.25 exercise price.

How many ATAI shares are underlying the new option grant?

The option grant covers 103,000 ATAI common shares.

When do the newly granted ATAI options vest?

They vest on the earlier of the day before ATAI’s next annual meeting or 26 June 2026.

Does the Form 4 indicate any purchase or sale of ATAI common shares?

No, the filing only reports an option award; no common shares were bought or sold.

What is the expiration date of the ATAI director’s new options?

The options expire on 26 June 2035.

Is the transaction part of a Rule 10b5-1 trading plan?

The filing does not mark the Rule 10b5-1 check-box, so no affirmative 10b5-1 plan is indicated.